Vir Biotechnology, Inc. (VIR)

8,81 +0,07 (+0,80%) A partir del 09:46AM EDT. Mercado abierto.

Vir Biotechnology, Inc.

1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 587

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.	CEO & Director	4,47M	N/A	1969
Mr. Sung H. Lee	Executive VP & CFO	968,45k	N/A	1970
Dr. Ann M. Hanly Ph.D.	Executive VP & Chief Technology Officer	896,07k	N/A	1970
Dr. Jeff Calcagno M.D.	Executive VP & Chief Business Officer	860,49k	N/A	1961
Dr. Klaus Frueh Ph.D.	Co-Founder & Scientific Advisor	177,66k	N/A	1960
Dr. Lawrence Corey M.D.	Co-Founder & Scientific Advisor	N/A	N/A	1948
Dr. Louis J. Picker M.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Jennifer Eileen Towne Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	N/A
Ms. Heather Rowe Armstrong	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Vanina De Verneuil J.D.	Executive VP, General Counsel & Corporate Secretary	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de Vir Biotechnology, Inc., a día 29 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 6; Tablero: 4; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.